期刊文献+

多发性硬化与视神经脊髓炎患者的基A-DRB1/DPB1因多态性 被引量:4

The polymorphism of HLA-DRB1/DPB1 in multiple sclerosis and optica neuromyelitis patients
下载PDF
导出
摘要 目的比较HLA-DRB1/DPB1基因多态性在多发性硬化(multiple sclerosis,MS)和视神经脊髓炎(neuromyelitis,NMO)患者中的分布差异,并进一步探讨与上述两种疾病的相关性。方法采集53例MS患者、30例NMO患者和93名健康对照人群的血样,提取DNA后用直接测序法对HLA-DRB1、DPB1基因进行高分辨四位分型,比较各组间不同基因分型的表达率并进一步进行单倍体分析。入组者均为我国南方汉族人群。结果DPB1*0501在NMO患者中的表达率高于对照组,P=0.001,校正后P=0.022;DRB1*1602 DPB1*0501单倍体在NMO患者中的表达率高于MS患者组,P<0.001,校正后P=0.040。结论在我国南方汉族人群中,MS、NMO患者HLA-DRB1/DPB1基因多态性存在明显差异,HLA-DPB1*0501可能是NMO发病的易感基因。 Objective To explore the role of the polymorphism of HLA-DRB1/DPB1 in patients with multiple scle-rosis (MS) and optica neuromyelitis (NMO). Methods Fifty-three patients with MS, 30 patients with NMO and 93 normal controls were enrolled in the present study. The HLA-DRB1/DPB1 gene polymorphism and allele frequencies were deter-mined by sequencing-based typing. All the subjects were Southern Han Chinese and were born in Southern China. Re-sults The frequencies of DPB1*0501 were higher in NMO patients than in controls, P=0.001, P (corrected)=0.022. The frequencies of DRB1*1602 DPB1*0501 haplotype were higher in NMO patients than in MS patients, P〈0.001,P (cor-rected)=0.040. Conclusions There is significant difference in HLA-DRB1/DPB1 gene polymorphism between MS and NMO patients in a Southern Han Chinese population. The HLA-DPB1*0501 allele might be the susceptibility gene poly-morphism of NMO.
出处 《中国神经精神疾病杂志》 CAS CSCD 北大核心 2014年第7期400-404,共5页 Chinese Journal of Nervous and Mental Diseases
关键词 多发性硬化 视神经脊髓炎 人类白细胞抗原 多态性 单倍体 Multiple sclerosis Neuromyelitis optica Human leucocyte antigen Polymorphism Haplotype
  • 相关文献

参考文献19

  • 1Long Y, Gao C, Qiu W, et al. Antibodies target microvessels in neuromyelitis optica and multiple sclerosis patients[J]. Neurol Res, 2013 , 35(9): 922-929.
  • 2冯金洲,张广慧,燕伟平,秦新月.雌激素抑制实验性自身免疫性脑脊髓炎大鼠的NF-κB和Rho激酶表达[J].中国神经精神疾病杂志,2013,39(8):479-483. 被引量:4
  • 3DeLuca GC, Ramagopalan SV, Herrera BM, et al. An extremes of outcome strategy provides evidence that multiple sclerosis se- verity is determined by alleles at the HLA-DRB1 locus[J]. Proc Natl Acad Sci USA, 2007,104(52): 20896-20901.
  • 4Cossburn M, Tackley G, Baker K, et al. The prevalence of neu- romyelitis optica in South East Wales[J]. Eur J Neurol, 2012,19 (4): 655-659.
  • 5Asgari N, Lillevang ST, Skejoe HP, et al. A population-based study of neuromyelitis optica in Caucasians[J]. Neurology.2011, 76(18):1589-1595.
  • 6Zophir H, Fajardy I, Outteryck O, et al. Is neuromyelitis optica associated with human leukocyte antigen?[J]. Mult Scler, 2009 , 15(5): 571-579.
  • 7Brum DG, Barreira AA, dos Santos AC. HLA-DRB association in neuromyelitis optica is different from that observed in multi- ple sclerosis[J]. Mult Scler, 2010,16(1): 21-29.
  • 8Kira J. Multiple sclerosis in the Japanese population[J]. Lancet Neurol, 2003, 2(2): 117-127.
  • 9Modin H, Olsson W, Hillert J, et al. Modes of Action of HLA-DR Susceptibility Specifieities in Multiple Sclerosis[J]. Am J Hum Genet, 2004,74(6): 1321-1322.
  • 10方丽波,刘广志,王拥军,张星虎.HLA-DRB1基因型与北方汉族多发性硬化易感性的研究[J].中国神经免疫学和神经病学杂志,2008,15(6):400-403. 被引量:12

二级参考文献25

  • 1吕传真,李振新,张华,戚晓昆,臧敬五.中国多发性硬化及相关中枢神经系统脱髓鞘疾病的诊断和治疗专家共识(草案)[J].中华神经科杂志,2006,39(12):862-864. 被引量:55
  • 2Masterman T, Ligers A, Olsson T, et al. HLADR15 is associated with lower age at onset in multiple sclerosis[J]. Ann Neurol, 2000, 48(2):211-219.
  • 3Olerup O, Zeuerquist H. HI.A-DR typing by PCR amplification with sequence-specific primers (PCRSSP)in 2 hours:An alterative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation [J]. Tissue Antigens, 1992,39(5): 225-235.
  • 4Fukazawa T, Yamasaki K, Ito H, et al. Both the HLA-CPB1 and- DRB1 alleles correlate with risk for multiple sclerosis in Japanese: clinical phenotypes and gender as important factors [J]. Tissue Antigens, 2000,55 (3): 199-205.
  • 5吴晓牧,张昆南,王朝东,熊英琼,柳喆,屈新辉,谢旭芳.人类白细胞抗原DRB1及DPB1等位基因多态性与南方部分地区汉族人多发性硬化的相关性研究[J].中华医学杂志,2007,87(39):2741-2744. 被引量:11
  • 6Yu JZ Ding J, Ma CG, et al. Therapeutie potential of experimen- tal autoimmune encephalomyelitis by Fasudil, a Rho kinase in- hibitor[J]. J Neurosci Res, 2010, 88(8): 1664-1672.
  • 7Chrissobolis S, Budzyn K, Mar|ey PD, et al. Evidence that estrn- gen suppresses rho-kinase function in the cerebral cireulatinn in vivo[J]. Stroke, 2004, 35(9): 2200-2205.
  • 8Pahan K, Schmid M. Activation of nuclear factor-kB in the spi- nal cord of experimental allergic encephalomyelitis[J]. Neurosci- ence Letter, 2000, 287(1): 17-20.
  • 9Bakir S, Mori T, Durand J, et al. Estrogen-induced vasoprotec- tion is estrogen receptor dependent: evidence from the bal- loon-injured rat carotid artery model [J]. Circulation, 2000, 101 (20): 2342-2344.
  • 10Han MH, Hwang SI, Roy DB, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets[J]. Nature, 2008, 451(7182): 1076-1081.

共引文献14

同被引文献28

  • 1田作军,赵薛旭,李作汉,张帆,曹福田,李少明,邵明.髓鞘碱性蛋白和白细胞介素16在多发性硬化发病机制和临床中的探讨[J].热带医学杂志,2006,6(8):883-885. 被引量:6
  • 2Haas J,Hug A,Viehover A,et al.Reduced suppressive effect of CD4^+CD25^high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with mul-tiple sclerosis[J].Eur J Immunol,2005,35(11):3343-3352.
  • 3Beyersdorf N,Gaupp S,Balbach K,et al.Selective targeting of regulatory T cells with CD28 superagonists allows effective thera-py of experimental autoimmune encephalomyelitis[J].J Exp Med,2005,202(3):445-455.
  • 4Polman C,Reingold S,Edan G,et al.Diagnostic criteria for mul-tiple sclerosis:2005 revisions to the 2001 McDonald criteria[J].Ann Neurol,2005,58(6):840-846.
  • 5Kataoka H,Takahashi S,Takase K,et al.CD25+CD4+regulato-ry Tcells exert in vitro suppressive activity independent of CT-LA-4[J].Int Immunol,2005,17(4):421-427.
  • 6Jun SM,Dchoa-Rep6raz J,Zlotkowska D,et al.Bystander-medi-ated stimulation of proteolipid protein-specific regulatory T(Treg)cells confers protection against experimental autoimmune encephalomyelitis(EAE)via TGF-β[J].Journal of Neuroimmu-nology,2012,245(1-2):39-47.
  • 7Ma A,Xiong Z,Hu Yx,et al.Dysfunction of IL-10-producing type I regulatory T cells and CD4+CD25+ regulatory T cells in a mimic model of human multiple sclerosis in Cynomolgus monkeys [J].International Immunopharmacology,2009,(9):599-608.
  • 8Putheti P,Soderstrom M,Link H,et al.Effect of glatiramer ace-tate(Copaxone)on CD4+ CD25high T regulatory cells and their IL-10 production in multiple sclerosis[J].Journal of Neuroimmu-nology,2003,144(1-2):125-131.
  • 9Thomas HR,Gitelman SE.Altering the course of type I diabetes:an update on prevention and new-onset clinical trials[J].Pediatr Diabetes,2013,14(5):311-321.
  • 10Trzonkowski P,Bieniaszewska M,JusciAska J,et al.First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+ CD25+ CD127 T regulatory cells[J].Clin Immunol,2009,133(1):22-26.

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部